Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenbailing Granules for Cancer-Related Fatigue in Breast Cancer
NCT06881550Enrolling by invitation
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Shenbailing in cancer-related fatigue (CRF) (2 arms). Primary endpoint: Piper Fatigue Assessment score at 28 days. Started Dec 2024; status: enrolling by invitation.
02
Drugs
Shenbailing
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT06881550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881550.